For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Visterra, Inc.

Calculating rank

USPTO Granted Patents = 38

% Expired Patents = 2.6

EPO Patents = 7

Trademarks = 7

Forward Citations = 82

Loading Chart...

Loading Chart...

33 inventors (with patents filed for the assignee):

Zachary Shriver (32 out of 85 patents)

Karthik Viswanathan (29 out of 40 patents)

Gregory Babcock (22 out of 34 patents)

4. Boopathy Ramakrishnan (21 out of 21 patents)

5. Andrew M Wollacott (18 out of 18 patents)

6. James R Myette (13 out of 28 patents)

7. Hedy Adari-Hall (8 out of 8 patents)

8. Brian Booth (7 out of 7 patents)

9. Luke Nathaniel Robinson (6 out of 8 patents)

10. Vidya Subramanian (5 out of 15 patents)

11. Sasisekharan Raguram (5 out of 5 patents)

12. Susan Sloan (4 out of 4 patents)

13. Obadiah Joseph Plante (4 out of 5 patents)

14. James C Delaney (3 out of 3 patents)

15. Lauren Olinski (3 out of 3 patents)

Core Competencies:

Interleukin-2 Agents

C5AR1 Antibodies

Dengue Virus

Humanized Antibodies

APRIL Antibodies

Antibody-Drug Conjugates

Polypeptides

Vaccine Formulations

IgA Nephropathy

Binding Agents

Synthetic Oligosaccharides

Influenza Treatments

38 patents: Sort by Forward Citations

1. 12642840 - Methods of using interleukin-2 agents (2026-06-02),

2. 12415865 - Antibody molecules to C5AR1 and uses thereof (2025-09-16),

3. 12338291 - Humanized antibody molecules to CD138 and uses thereof (2025-06-24),

4. 12297249 - Interleukin-2 agents and uses thereof (2025-05-13),

5. 12264203 - Humanized complement 5a receptor 1 antibodies and methods of use thereof (2025-04-01),

6. 12227587 - Humanized complement 5A receptor 1 antibodies and methods of use thereof (2025-02-18),

7. 12202885 - Formulations of antibody molecules to influenza virus (2025-01-21),

8. 12187807 - Antibody molecules to C5AR1 and uses thereof (2025-01-07),

9. 12098178 - Methods of using interleukin-2 agents (2024-09-24),

10. 12091451 - Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL) (2024-09-17),

11. 12084484 - Interleukin-2 agents and uses thereof (2024-09-10),

12. 12054539 - Antibody molecules to dengue virus and uses thereof (2024-08-06),

13. 12024552 - Ha binding agents (2024-07-02),

14. 11969476 - Antibody molecule-drug conjugates and uses thereof (2024-04-30),

15. 11945868 - Antibody molecules to CD138 and uses thereof (2024-04-02),

Company Overview

Visterra, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing innovative therapeutic solutions for infectious diseases and other serious health conditions. The company specializes in leveraging its proprietary platform to design and engineer monoclonal antibodies and other biologics, aiming to enhance treatment efficacy and patient outcomes. Visterra's research emphasizes the intersection of immunology and molecular biology, positioning it as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

38 Patents

#40 in Waltham, MA

#526 in Massachusetts

#9,033 in US

#17,860 in the World

Waltham, MA, United States of America

Visterra, Inc.

Forward Citations = 82

33 inventors:

Zachary Shriver (32 out of 85 patents)

Karthik Viswanathan (29 out of 40 patents)

Gregory Babcock (22 out of 34 patents)

4. Boopathy Ramakrishnan (21 out of 21 patents)

5. Andrew M Wollacott (18 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Visterra, Inc.. Retrieved from https://idiyas.com/company/visterra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…